The maker of weight loss drugs Ozempic and Wegovy broke rules around the advertising and marketing of its medication to healthcare workers over three years, the medicines watchdog has found.

Novo Nordisk (NVO) is offering a one-month reduction ... drugs and are seeking access to authentic, FDA-approved Wegovy," the company said in a statement Thursday. Semaglutide is the key ...

Amycretin, the Danish drugmaker’s next-generation obesity drug, has a dual-mode action. Like its popular weight-loss drug ...

COPENHAGEN (Reuters) -Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug ...

May 22 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it would offer temporary discounts to cash-paying customers for its weight-loss drug Wegovy, in a move that coincides ...

Deep Apple discovers drug candidates using its AI-based platform that screens virtual libraries of billions of compounds to ...

It's been a tough year for Novo Nordisk, the Danish pharmaceutical company behind the GLP-1 drugs Ozempic and Wegovy. Competitors are nipping at its heels, cheaper knockoffs have been eating into ...

After that, a month’s supply (28 days of 2.4 mg doses) will cost $499, according to Novo Nordisk. The company noted patients can also check Wegovy.com to see if their commercial insurance ...

Many cite cost as the limiting factor. Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, for example, are listed at about $1,350 and $1,060 per month respectively before any discounts ...

Novo Nordisk hopes to receive regulatory approval to market and sell its semaglutide weight loss drug Wegovy in pill form by year-end. Meanwhile, CagriSema, currently in phase 3 clinical trials ...

Years before Novo Nordisk's (NOVOb.CO), opens new tab obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press conference in Copenhagen: "You ain't seen nothing yet." ...